Jim Cramer answers viewers' Twitter questions from the floor of the New York Stock Exchange. Cramer answers his first question on the IT consulting company, Cognizant (CTSH). Cognizant beat earnings and revenue estimates in its last earnings report but Cramer thinks that the stock is ‘played out.’ The problem Cramer has with Cognizant, which continues to beat estimates again and again, is that ‘eventually expectations catch up.’ Looking to retail stocks, Cramer says that ‘if you like J.C. Penney (JCP), go buy Macy's (M), go buy Target (TGT); they’re all going to move.’ Action Alerts PLUS, Cramer’s charitable portfolio, owns Target. Cramer admits that ‘the stock has been terrible of late,’ but thinks that ‘Target is going to have an okay season.’ ‘More importantly Brian Cornell is turning the company around,’ Cramer said. ‘If you look at a snapshot month to month or even one quarter, you are making a mistake. Target is back. It is going to be really good.’ Cramer answered a question on Priceline (PCLN). ‘I’ve liked Priceline for a long time’ he said, adding that that ‘European bookings and travel is very strong.’ Cramer also said that Kayak (KYAK) is also ‘very strong’ and that Kayak matters a great deal for the group, a group which Cramer says is ‘on fire.’ Cramer ends by saying that he thinks Expedia (EXPE) and Priceline are great and that he thinks Priceline ‘can go a lot higher.’ If you have a stock question, tweet it @jimcramer using #CramerQ
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.